Polio Vaccine Market Revenue to Attain USD 1.63 Bn by 2033


24 Jun 2025

Share : linkedin twitter facebook

The global polio vaccine market revenue reached USD 1.19 billion in 2025 and is predicted to attain around USD 1.63 billion by 2033 with a CAGR of 4.05%. The rising global immunization program and increasing awareness about disease prevalence are boosting the growth of the market. Furthermore, rising development of novel vaccine formulations opens up new growth avenues.

Polio Vaccine Market Revenue Statistics

Market Overview

The polio vaccine market is experiencing rapid growth due to the increasing immunization programs around the world to reduce the prevalence of polio. Governments around the world are supporting vaccination programs, particularly in undeveloped regions. Healthcare organizations such as WHO, UNICEF, and GAVI are launching mass polio vaccination programs to eradicate poliovirus, which drives the growth of the market. In addition, the rising birth rates in polio-prone countries, as well as improved healthcare infrastructure, further support the uptake of vaccines.

The rising development of novel vaccines creates immense opportunities in the market. Technological advances enable the development of new formulations, enhancing the efficacy of vaccines. Moreover, ongoing research and strategic partnerships are producing low-cost, temperature-stable vaccines designed for hard-to-reach and underserved populations.

Segment Insights

  • By type, the inactivated polio vaccine (IPV) segment held the largest share of the market in 2024. This is mainly due to a very high global level of acceptance of IPVs in routine immunization programs for their enhanced safety profile.
  • By application, the public segment led the market with the biggest share in 2024. Due to the increased public health concerns, governments, as well as the public sector around the world, are making efforts to eradicate polio worldwide. Global programs like Gavi are attempting to eradicate polio in endemic locations, supporting segmental growth.
  • By end-user, the hospitals & clinics segment contributed the largest market share in 2024. As a primary healthcare center that routinely administers immunizations and addresses polio emergencies, there is high demand for polio vaccines in hospitals. These settings have a track record of being the most effective place to administer vaccines due to their infrastructure, trained personnel, and access to a diverse patient population.

Regional Insights

In 2024, North America led the polio vaccine market with a major revenue share. The region has an advanced healthcare system, facilitating efficient distribution and administration of vaccines. The region also has a well-established retail chain, ensuring a steady supply of polio vaccines. In addition, increased vaccination programs bolstered the growth of the market within the region.

Meanwhile, Asia Pacific is expected to grow at the fastest rate during the forecast period. This is mainly due to the rising birth rates, leading to a high demand for polio vaccines. Governments of various Asian Countries are focusing on increasing vaccination rates to eradicate polio. The WHO has certified South-East Asia as polio-free since 2014. However, wild poliovirus remains persistent in Afghanistan and Pakistan, boosting the demand for polio vaccines.

Polio Vaccine Market Coverage

Report Attribute Key Statistics
Market Revenue in 2025 USD 1.19 Billion
Market Revenue by 2033 USD 1.63 Billion
CAGR from 2025 to 2033     4.05%
Quantitative Units Revenue in USD million/billion, Volume in units
Largest Market North America
Base Year 2024
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Recent Development

  • In July 2024, the WHO granted pre‑qualification status to Biological E’s novel oral polio vaccine type 2 (nOPV2), enabling large-scale rollout with improved genetic stability and reduced vaccine-derived outbreak risk.
    (Source: https://www.thehindu.com)

Polio Vaccine Market Key Players

  • Sanofi
  • GSK
  • Bibcol
  • Serum Institute
  • Tiantan Biological
  • IMBCA
  • Panacea Biotec Ltd
  • Bio-Med
  • Halfkin Bio-Pharmaceuticals
  • GlaxoSmithKline
  • Merck & Co
  • CSL Limited

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6277

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com|+1 804 441 9344

Related Reports